Drugs / Thymol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05427721 | Apr → Dec 2022 | inflammatory disease, obesity disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03179735 | Jun 2017 → Mar 2018 | gingivitis | University of Taubate | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thymol | “containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)” NCT03179735 ↗ |